Ethnicity matters: A Systematic Review and Meta-Analysis of the Non-Linear Relationship Between Alcohol Consumption and Prevalence and Incidence of Hepatic Steatosis

EBioMedicine

Volumn 8, Issue , 2016, Pages 317-330

  Roerecke, Michael ^a,b   Nanau, Radu ^c   Rehm, Jürgen ^a,b,d,e   Neuman, Manuela ^c,d,f,g  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c In Vitro Drug Safety and Biotechnology   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f FUNDENI CLINICAL INSTITUTE   (Romania)

^g CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Alcohol drinking; Alcoholic fatty liver; Binge drinking; Incidence; Meta analysis; Non alcoholic fatty liver; Prevalence; Systematic review

Indexed keywords

ALCOHOL CONSUMPTION; ARTICLE; BINGE DRINKING; DISEASE ASSOCIATION; DOSE RESPONSE; ETHNICITY; FATTY LIVER; GENDER; HISTOPATHOLOGY; HUMAN; INCIDENCE; JAPAN; LIVER BIOPSY; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; SYSTEMATIC REVIEW (TOPIC); ADVERSE EFFECTS; DRINKING BEHAVIOR; ETHNIC GROUP; ETHNOLOGY; FEMALE; HEALTH SURVEY; MALE; META ANALYSIS; ODDS RATIO; RISK FACTOR;

ALCOHOL DRINKING; ETHNIC GROUPS; FATTY LIVER; FEMALE; HUMANS; INCIDENCE; JAPAN; MALE; ODDS RATIO; POPULATION SURVEILLANCE; PREVALENCE; RISK FACTORS;

EID: 84964687504     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.04.023     Document Type: Article

References (88)

1. Attvall S., Fowelin J., Lager I., Von Schenck H., Smith U. Smoking induces insulin resistance-a potential link with the insulin resistance syndrome. J. Intern. Med. 1993, 233(4):327-332.
2. Ballestri S., Zona S., Targher G., et al. Nonalcoholic Fatty Liver Disease Is Associated with an almost two-Fold Increased Risk of Incident Type 2 Diabetes and Metabolic Syndrome 2015, Evidence from a systematic review and meta-analysis, Journal of Gastroenterology and Hepatology, (Epub ahead of print). 10.1111/jgh.13264.
3. Bellentani S., Saccoccio G., Costa G., et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Dionysos Study Group. Gut 1997, 41(6):845-850.
4. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 2000, 132(2):112-117.
5. Bonci E., Chiesa C., Versacci P., Anania C., Silvestri L., Pacifico L. Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: a systematic review and meta-analysis. BioMed Res. Int. 2015, 2015:213737.
6. Brien S.E., Ronksley P.E., Turner B.J., Mukamal K.J., Ghali W.A. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ 2011, 342:d636.
7. Byass P. The global burden of liver disease: a challenge for methods and for public health. BMC Med. 2014, 12:159.
8. Byrne C.D., Targher G. NAFLD: a multisystem disease. J. Hepatol. 2015, 62(1 Suppl):S47-S64.
9. Caballeria L., Pera G., Auladell M.A., et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur. J. Gastroenterol. Hepatol. 2010, 22(1):24-32.
10. Chalasani N., Younossi Z., Lavine J.E., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55(6):2005-2023.
11. Chalmers T.C., Smith H., Blackburn B., et al. A method for assessing the quality of a randomized control trial. Control. Clin. Trials 1981, 2(1):31-49.
12. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7(3):177-188.
13. Detsky A.S., Naylor C.D., O'Rourke K., McGeer A.J., L'Abbe K.A. Incorporating variations in the quality of individual randomized trials into meta-analysis. J. Clin. Epidemiol. 1992, 45(3):255-265.
14. Doi T., Tanaka S., Sato Y., et al. Effect of alcohol consumption on the prevalence of fatty liver disease. Acta Hepato. Jpn. 2010, 51(9):501-507.
15. EASL Clinical practical guidelines: management of alcoholic liver disease. J. Hepatol. 2012, 57(2):399-420.
16. Egger M., Smith G.D., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
17. Freeman M.F., Tukey J.W. Transformations related to the angular and the square root. Ann. Math. Stat. 1950, 21(4):607-611.
18. Greenfield T.K. Ways of measuring drinking patterns and the difference they make: experience with graduated frequencies. J. Subst. Abus. 2000, 12(1-2):33-49.
19. Greenland S., O'Rourke K. On the bias produced by quality scores in meta-analysis, and a hierarchical view of proposed solutions. Biostatistics 2001, 2(4):463-471.
20. Grove J., Daly A.K., Bassendine M.F., Day C.P. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997, 26(1):143-146.
21. Gunji T., Matsuhashi N., Sato H., et al. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population. Am. J. Gastroenterol. 2009, 104(9):2189-2195.
22. Hamabe A., Uto H., Imamura Y., et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J. Gastroenterol. 2011, 46(6):769-778.
23. Hamaguchi M., Kojima T., Takeda N., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005, 143(10):722-728.
24. Hamaguchi M., Kojima T., Ohbora A., Takeda N., Fukui M., Kato T. Protective effect of alcohol consumption for fatty liver but not metabolic syndrome. World J. Gastroenterol. 2012, 18(2):156-167.
25. Hamling J., Lee P., Weitkunat R., Ambuhl M. Facilitating meta-analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat. Med. 2008, 27(7):954-970.
26. Hashimoto Y., Hamaguchi M., Kojima T., et al. Modest alcohol consumption reduces the incidence of fatty liver in men: a population-based large-scale cohort study. J. Gastroenterol. Hepatol. 2015, 30(3):546-552.
27. Herbison P., Hay-Smith J., Gillespie W.J. Adjustment of meta-analyses on the basis of quality scores should be abandoned. J. Clin. Epidemiol. 2006, 59(12):1249-1256.
28. Hernaez R., Lazo M., Bonekamp S., et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011, 54(3):1082-1090.
29. Higgins J., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21(11):1539-1558.
30. Hiramine Y., Imamura Y., Uto H., et al. Alcohol drinking patterns and the risk of fatty liver in Japanese men. J. Gastroenterol. 2011, 46(4):519-528.
31. Kerr W.C., Fillmore K.M., Bostrom A. Stability of alcohol consumption over time: evidence from three longitudinal surveys from the United States. J. Stud. Alcohol 2002, 63(3):325-333.
32. Knott C., Bell S., Britton A. Alcohol consumption and the risk of type 2 diabetes: a systematic review and dose-response Meta-analysis of >1.9 million individuals from 38 observational studies. Diabetes Care 2015, 38(9):1804-1812.
33. LaBrecque D.R., Abbas Z., Anania F., et al. World gastroenterology organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2014, 48(6):467-473.
34. Lau K., Baumeister S.E., Lieb W., et al. The combined effects of alcohol consumption and body mass index on hepatic steatosis in a general population sample of European men and women. Aliment. Pharmacol. Ther. 2015, 41(5):467-476.
35. Lazo Elizondo M. Epidemiology of Nonalcoholic Fatty Liver Disease in the United States: Prevalence, Correlates and Mortality 2010, John Hopkins University, Baltimore, MD.
36. Li L., Liu D.W., Yan H.Y., Wang Z.Y., Zhao S.H., Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes. Rev.: Off J. Int. Assoc Study Obes. 2016.
37. Li X.H., Yu F.F., Zhou Y.H., He J. Association between alcohol consumption and the risk of incident type 2 diabetes: a systematic review and dose-response meta-analysis. Am. J. Clin. Nutr. 2016.
38. Lieber C.S. CYP2E1: from ASH to NASH. Hepatol. Res. 2004, 28(1):1-11.
39. Liu P.J., Ma F., Lou H.P., Zhu Y.N., Chen Y. Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women. Climacteric 2014, 17(6):692-699.
40. Loria P., Marchesini G., Nascimbeni F., et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014, 232(1):99-109.
41. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012, 380(9859):2095-2128.
42. Lu H., Liu H., Hu F., Zou L., Luo S., Sun L. Independent association between nonalcoholic fatty liver disease and cardiovascular disease: a systematic review and meta-analysis. Int. J. Endocrinol. 2013, 2013:124958.
43. Mathurin P., Deltenre P. Effect of binge drinking on the liver: an alarming public health issue?. Gut 2009, 58(5):613-617.
44. Matsuura B., Nunoi H., Miyake T., Hiasa Y., Onji M. Obesity and gastrointestinal liver disorders in Japan. J. Gastroenterol. Hepatol. 2013, 28(Suppl. 4):48-53.
45. Miele L., Dall'armi V., Cefalo C., et al. A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease. Genes Nutr. 2014, 9(2):383.
46. Vital signs: Binge drinking prevalence, frequency, and intensity among adults - United States. MMWR Morb. Mortal. Wkly Rep. 2012 2010, 61(1):14-19.
47. Moher D., Pham B., Jones A., et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998, 352(9128):609-613.
48. Moriya A., Iwasaki Y., Ohguchi S., et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2011, 33(3):378-388.
49. Moriya A., Iwasaki Y., Ohguchi S., et al. Roles of alcohol drinking pattern in fatty liver in Japanese women. Hepatol. Int. 2013, 7(3):859-868.
50. Moriya A., Iwasaki Y., Ohguchi S., et al. Roles of alcohol consumption in fatty liver: a longitudinal study. J. Hepatol. 2015, 62(4):921-927.
51. Naimi T.S., Brewer R.D., Mokdad A., Denny C., Serdula M.K., Marks J.S. Binge drinking among US adults. JAMA 2003, 289(1):70-75.
52. Nascimbeni F., Pais R., Bellentani S., et al. From NAFLD in clinical practice to answers from guidelines. J. Hepatol. 2013, 59(4):859-871.
53. Naveau S., Thaury J., Barri-Ova N., et al. Predictive factors for pure steatosis in alcoholic patients. Alcohol. Clin. Exp. Res. 2009, 33(6):1104-1110.
54. Naveau S., Dobrin A.S., Balian A., et al. Body fat distribution and risk factors for fibrosis in patients with alcoholic liver disease. Alcohol. Clin. Exp. Res. 2013, 37(2):332-338.
55. Neuman M.G. Cytokines-central factors in alcoholic liver disease. Alcohol Res. Health 2003, 27(4):307-316.
56. Neuman M.G., Cohen L.B., Nanau R.M. Biomarkers in nonalcoholic fatty liver disease. Can. J. Gastroenterol. Hepatol. 2014, 28(11):607-618.
57. Neuman M.G., French S.W., French B.A., et al. Alcoholic and non-alcoholic steatohepatitis. Exp. Mol. Pathol. 2014, 97(3):492-510.
58. Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat. Med. 1998, 17(8):857-872.
59. Nishioji K., Sumida Y., Kamaguchi M., et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012. J. Gastroenterol. 2015, 50(1):95-108.
60. Orsini N., Bellocco R., Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J. 2006, 6(1):40-57.
61. Orsini N., Li R., Wolk A., Khudyakov P., Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am. J. Epidemiol. 2012, 175(1):66-73.
62. Peng X.E., Lai Z.S., Lu Q.Q., Lin J.Y., Lin X. A hospital-based case-control study on influencing factors of nonalcoholic fatty liver disease. Chin. J. Hepatol. 2009, 17(7):535-539.
63. Poli A., Marangoni F., Avogaro A., et al. Moderate alcohol use and health: a consensus document. Nutr. Metab. Cardiovasc. Dis. 2013, 23(6):487-504.
64. Raynard B., Balian A., Fallik D., et al. Risk Factors of Fibrosis in Alcohol-Induces Liver Diseases. Hepatology 2002, 35(3):635-638. Baltimore, Md.
65. Rehm J., Roerecke M. Patterns of drinking and liver cirrhosis - what do we know and where do we go?. J. Hepatol. 2015, 62(5):1000-1001.
66. Rehm J., Irving H., Ye Y., Kerr W.C., Bond J., Greenfield T.K. Are lifetime abstainers the best control group in alcohol epidemiology? On the stability and validity of reported lifetime abstention. Am. J. Epidemiol. 2008, 168(8):866-871.
67. Roerecke M., Rehm J. Cause-specific mortality risk in alcohol use disorder treatment patients: a systematic review and meta-analysis. Int. J. Epidemiol. 2014, 43(3):906-919.
68. Roerecke M., Rehm J. Alcohol consumption, drinking patterns, and ischemic heart disease: a narrative review of meta-analyses and a systematic review and meta-analysis of the impact of heavy drinking occasions on risk for moderate drinkers. BMC Med. 2014, 12:182.
69. Sattar N., Forrest E., Preiss D. Non-alcoholic fatty liver disease. BMJ 2014, 349:g4596.
70. Schrieks I.C., Heil A.L., Hendriks H.F., Mukamal K.J., Beulens J.W. The effect of alcohol consumption on insulin sensitivity and glycemic status: a systematic review and meta-analysis of intervention studies. Diabetes Care 2015, 38(4):723-732.
71. Shield K.D., Rylett M., Gmel G., Gmel G., Kehoe-Chan T.A., Rehm J. Global alcohol exposure estimates by country, territory and region for 2005-a contribution to the comparative risk assessment for the 2010 global burden of disease study. Addiction 2013, 108(5):912-922.
72. Stroup D.F., Berlin J.A., Morton S.C., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283(15):2008-2012.
73. Sun K., Ren M., Liu D., Wang C., Yang C., Yan L. Alcohol consumption and risk of metabolic syndrome: a meta-analysis of prospective studies. Clin. Nutr. 2014, 33(4):596-602.
74. Suomela E., Oikonen M., Virtanen J., et al. Prevalence and determinants of fatty liver in normal-weight and overweight young adults. The cardiovascular risk in young Finns study. Ann. Med. 2015, 47(1):40-46.
75. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010, 363(14):1341-1350.
76. Thompson S.G., Higgins J.P. How should meta-regression analyses be undertaken and interpreted?. Stat. Med. 2002, 21(11):1559-1573.
77. Tsunoda K., Kai Y., Uchida K., Kuchiki T., Nagamatsu T. Physical activity and risk of fatty liver in people with different levels of alcohol consumption: a prospective cohort study. BMJ Open 2014, 4(8).
78. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011, 34(3):274-285.
79. Volzke H. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin?. World J. Gastroenterol. 2012, 18(27):3492-3501.
80. WHO International Guide for Monitoring Alcohol Consumption and Related Harm 2000, Geneva, Switzerland.
81. Will J.C., Galuska D.A., Ford E.S., Mokdad A., Calle E.E. Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. Int. J. Epidemiol. 2001, 30(3):540-546.
82. Wong V.W., Chu W.C., Wong G.L., et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012, 61(3):409-415.
83. Xu C., Yu C., Xu L., Miao M., Li Y. High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. PLoS One 2010, 5(7).
84. Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diab. Endocrinol. 2014, 2(11):901-910.
85. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of non-alcoholic fatty liver disease-Meta-analytic assessment of prevalence. Incidence Outcomes. Hepatology 2015, (Epub ahead of print). 10.1002/hep.28431.
86. Zein C.O. Clearing the smoke in chronic liver diseases. Hepatology 2010, 51(5):1487-1490.
87. Zimmerman H. Adverse Effects of Drugs and Other Chemicals on the Liver 1999, Lippincott-Williams-Wilkins, Philadelphia. second ed.
88. Zimmerman H.J., Ishak K.G. Non-alcoholic steatohepatitis and other forms of pseudoalcoholic liver disease. Alcoholic Liver Disease Pathology and Pathogenesis 1955, 165-198. Edward Arnold, London. second ed. P. Hall (Ed.).